Compliance of Patients With Essential Hypertension Treated With Candesartan or Candesartan/Hydrochlorothiazide

AstraZeneca0 个研究点目标入组 1,773 人开始时间: 2007年1月最近更新: 2008年2月6日

适应症

试验速览

阶段: 不适用
状态: 已完成
发起方: AstraZeneca
入组人数: 1,773
主要终点: To estimate under naturalistic conditions the compliance rate, defined as the number of subjects with regular intake of the prescribed dose of candesartan or candesartan/HCT as judged by the physician at the end of the observational period.

研究概览研究设计入排标准结局指标研究者记录与标识符相似试验

研究概览

简要总结

The CoCa study with at maximum daily dose of 32 mg candesartan or 16/12.5 mg candesartan/hydrochlorothiazide has the objective to evaluate under naturalistic conditions, i.e. under routine medical care conditions, the subject compliance as well as the efficacy and tolerability of candesartan or candesartan/HCT in subjects suffering from essential hypertension.

研究设计

研究类型: Observational
观察模型: Cohort
时间视角: Prospective

入排标准

接受健康志愿者: 否

入选标准

•essential hypertension
•under candesartan treatment

排除标准

未提供

结局指标

主要结局

To estimate under naturalistic conditions the compliance rate, defined as the number of subjects with regular intake of the prescribed dose of candesartan or candesartan/HCT as judged by the physician at the end of the observational period.

时间窗: app. 3 monthly

次要结局

To assess under naturalistic conditions the subject's reason(s) for being compliant or non-compliant with the intake of the pre-scribed dose of candesartan or candesartan/HCT(app. 3 monthly)
To assess under naturalistic conditions the subject's reason(s) for withdrawal of the pre-scribed dose of candesartan or candesartan/HCT(app. 3 monthly)
To assess under naturalistic conditions whether physicians are using procedures to improve the subject's compliance regarding the intake of candesartan or candesartan/HCT and to get insight in the type and effects of these procedures(app. 3 monthly)

研究者

发起方

AstraZeneca

申办方类型

Industry

相似试验

已完成

不适用

Candesartan and Candesartan/ Hydrochlorothiazide in the Treatment of Patients With Hypertension and LVHEssential HypertensionLeft Ventricular Hypertrophy

NCT00607633AstraZeneca686

已完成

不适用

Blopress Tablets Specified Drug-use Survey "Hypertension: Survey on Patients With Metabolic Syndrome"Hypertension

NCT02166697Takeda14,151

已完成

4 期

Candesartan Antihypertensive Survival Evaluation in Japan (CASE-J) Trial of Cardiovascular Events in High-Risk Hypertensive PatientsHypertension

JPRN-C000000267EBM Collaborating Research Center in Kyoto University4,000

已完成

不适用

COmpliance and Efficacy in Mono and Combination Tablet Study ATacand/Atacand PlusHypertension

NCT00526279AstraZeneca9,000

已完成

3 期

A Long-term Study of CS-3150 as monotherapy or in combination with other antihypertensive drug in Japanese Patients with Essential HypertensioEssential hypertension

JPRN-jRCT2080223121DAIICHI SANKYO Co.,Ltd.368